Cargando…

Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice

Diabetic kidney disease (DKD) is appeared to be higher risk of declining kidney function compared to non-diabetic kidney disease with same magnitude of albuminuria. Epithelial-mesenchymal transition (EMT) program of tubular epithelial cells (TECs) could be important for the production of the extrace...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takagaki, Yuta, Shi, Sen, Katoh, Makoto, Kitada, Munehiro, Kanasaki, Keizo, Koya, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525172/ https://www.ncbi.nlm.nih.gov/pubmed/31101909 http://dx.doi.org/10.1038/s41598-019-43730-5

Ejemplares similares

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway
por: Kawakita, Emi, et al.
Publicado: (2023)

Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium–glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin‐overloaded streptozotocin‐induced diabetic mice
por: Shimada, Keiji, et al.
Publicado: (2022)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
por: Li, Shaolan, et al.
Publicado: (2020)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
por: Kanasaki, Keizo, et al.
Publicado: (2013)

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet
por: Takagi, Susumu, et al.
Publicado: (2018)

N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
por: Kanasaki, Keizo, et al.
Publicado: (2014)

CD‐1(db/db) mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis
por: Mizunuma, Yuiko, et al.
Publicado: (2020)

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
por: Nitta, Kyoko, et al.
Publicado: (2016)

Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
por: Kanasaki, Megumi, et al.
Publicado: (2011)

Diabetic angiopathy and angiogenic defects
por: Xu, Ling, et al.
Publicado: (2012)

N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014)

The PKM2 activator TEPP‐46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF‐1α accumulation
por: Liu, Haijie, et al.
Publicado: (2020)

Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2016)

Sirtuins and renal diseases: relationship with aging and diabetic nephropathy
por: Kitada, Munehiro, et al.
Publicado: (2012)

Dietary Restriction Ameliorates Diabetic Nephropathy through Anti-Inflammatory Effects and Regulation of the Autophagy via Restoration of Sirt1 in Diabetic Wistar Fatty (fa/fa) Rats: A Model of Type 2 Diabetes
por: Kitada, Munehiro, et al.
Publicado: (2011)

βklotho is essential for the anti‐endothelial mesenchymal transition effects of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline
por: Gao, Rongfen, et al.
Publicado: (2019)

Renal mitochondrial oxidative stress is enhanced by the reduction of Sirt3 activity, in Zucker diabetic fatty rats
por: Ogura, Yoshio, et al.
Publicado: (2018)

Classical molecule in diabetic kidney hypertrophy is linked to defects in self‐eating through fine‐tuning
por: Takagaki, Yuta, et al.
Publicado: (2021)

SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2018)

Autophagy as a Therapeutic Target in Diabetic Nephropathy
por: Tanaka, Yuki, et al.
Publicado: (2012)

A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity
por: Kitada, Munehiro, et al.
Publicado: (2018)

Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice
por: Kanasaki, Megumi, et al.
Publicado: (2017)

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway
por: Li, Jinpeng, et al.
Publicado: (2017)

Restoration of the Hypothalamic-pituitary-adrenal Response to Hypoglycemia in Type 2 Diabetes by Avoiding Chronic Hypoglycemia
por: Tsuda, Shin-ichi, et al.
Publicado: (2016)

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
por: Kitada, Munehiro, et al.
Publicado: (2017)

NAD(+) Homeostasis in Diabetic Kidney Disease
por: Xu, Jing, et al.
Publicado: (2021)

Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis
por: Kanasaki, Keizo, et al.
Publicado: (2013)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Severe electrolytes disorders with the interstitial kidney alterations in the patient with the history of total thyroidectomy and parathyroidectomy: possible role of vitamin D deficiency
por: Kawakita, Emi, et al.
Publicado: (2018)

MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT
por: Srivastava, Swayam Prakash, et al.
Publicado: (2013)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

A Low-Protein Diet for Diabetic Kidney Disease: Its Effect and Molecular Mechanism, an Approach from Animal Studies
por: Kitada, Munehiro, et al.
Publicado: (2018)

Biology of Obesity: Lessons from Animal Models of Obesity
por: Kanasaki, Keizo, et al.
Publicado: (2011)

SIRT1 in Type 2 Diabetes: Mechanisms and Therapeutic Potential
por: Kitada, Munehiro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_scc5rihtrqdpc81dj11qn933n1